Boston Scientific Dirección
Dirección controles de criterios 3/4
El CEO de Boston Scientific es Mike Mahoney , nombrado en Oct 2011, tiene una permanencia de 13.08 años. compensación anual total es $18.72M, compuesta por 7.5% salario y 92.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.12% de las acciones de la empresa, por valor de $156.52M. La antigüedad media del equipo directivo y de la junta directiva es de 8.6 años y 8.3 años, respectivamente.
Información clave
Mike Mahoney
Chief Executive Officer (CEO)
US$18.7m
Compensación total
| Porcentaje del salario del CEO | 7.5% |
| Permanencia del CEO | 13.1yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 8.6yrs |
| Promedio de permanencia en la Junta Directiva | 8.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Why The Fundamentals Make Me Bullish On Boston Scientific
Oct 31Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Oct 23Is Boston Scientific (NYSE:BSX) A Risky Investment?
Oct 10
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement
Sep 24Boston Scientific: Forward Returns Are Likely To Be Disappointing For Investors
Sep 20Boston Scientific Corporation's (NYSE:BSX) P/E Still Appears To Be Reasonable
Sep 09A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 23The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Compensación vs. Mercado: La compensación total de Mike($USD18.72M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD12.74M).
Compensación vs. Ingresos: La compensación de Mike ha sido consistente con los resultados de la empresa en el último año.
CEO
Mike Mahoney (59 yo)
13.1yrs
Permanencia
US$18,723,735
Compensación
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$18.72m | 0.12% $ 156.5m | |
| Executive VP & CFO | 10.8yrs | US$5.83m | 0.015% $ 20.2m | |
| Executive VP & Group President of Cardiology | 14.8yrs | US$5.59m | 0.011% $ 15.0m | |
| Executive VP & President of Peripheral Interventions | 11.8yrs | US$3.78m | 0.0019% $ 2.5m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.3yrs | US$4.27m | 0.0016% $ 2.2m | |
| Executive Vice President of Global Operations | 2.5yrs | sin datos | 0.0025% $ 3.4m | |
| Senior VP | less than a year | sin datos | 0.00026% $ 346.6k | |
| Senior VP and Chief Information & Digital Officer | 8.9yrs | sin datos | sin datos | |
| Senior VP of Investor Relations | less than a year | sin datos | 0.0026% $ 3.4m | |
| Senior VP | 3.4yrs | sin datos | 0.0023% $ 3.1m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.5yrs | sin datos | sin datos | |
| Executive Vice President of Human Resources | 11.9yrs | sin datos | 0.0022% $ 2.9m |
8.6yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BSX es experimentado (8.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 12yrs | US$18.72m | 0.12% $ 156.5m | |
| Lead Independent Director | 10.7yrs | US$360.00k | 0.0030% $ 4.0m | |
| Independent Director | 8.6yrs | US$335.00k | 0.0033% $ 4.4m | |
| Independent Director | 8.3yrs | US$320.00k | 0.00020% $ 266.6k | |
| Independent Director | 3.4yrs | US$338.75k | 0.0027% $ 3.6m | |
| Director | less than a year | sin datos | sin datos | |
| Director | less than a year | sin datos | 0.00024% $ 319.9k | |
| Independent Director | 9.6yrs | US$326.25k | 0.0043% $ 5.7m | |
| Independent Director | 15.6yrs | US$340.00k | 0.0036% $ 4.8m | |
| Independent Director | 1.4yrs | US$233.23k | 0.00042% $ 559.9k | |
| Independent Director | 1.4yrs | US$233.23k | 0.00027% $ 359.9k |
8.3yrs
Permanencia media
60.5yo
Promedio de edad
Junta con experiencia: La junta directiva de BSX se considera experimentada (8.3 años de antigüedad promedio).